196 related articles for article (PubMed ID: 15780414)
1. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo.
Darouiche RO; Mansouri MD
J Infect; 2005 Apr; 50(3):206-9. PubMed ID: 15780414
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy of antimicrobial-coated fabric from prosthetic heart valve sewing rings.
Darouiche RO; Meade R; Mansouri M; Raad II
J Heart Valve Dis; 1998 Nov; 7(6):639-46. PubMed ID: 9870198
[TBL] [Abstract][Full Text] [Related]
3. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
[TBL] [Abstract][Full Text] [Related]
4. Vascular graft infection by Staphylococcus aureus: efficacy of cefazolin, teicoplanin and vancomycin prophylaxis protocols in a rat model.
Atahan E; Gul M; Ergun Y; Eroglu E
Eur J Vasc Endovasc Surg; 2007 Aug; 34(2):182-7. PubMed ID: 17481929
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.
Raad I; Darouiche R; Vazquez J; Lentnek A; Hachem R; Hanna H; Goldstein B; Henkel T; Seltzer E
Clin Infect Dis; 2005 Feb; 40(3):374-80. PubMed ID: 15668859
[TBL] [Abstract][Full Text] [Related]
6. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections.
Goldstein BP; Jones RN; Fritsche TR; Biedenbach DJ
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):83-7. PubMed ID: 16458124
[TBL] [Abstract][Full Text] [Related]
7. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.
Lopez S; Hackbarth C; Romanò G; Trias J; Jabes D; Goldstein BP
J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii21-4. PubMed ID: 15750033
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin: a review for dermatologists.
Scheinfeld N
Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
[TBL] [Abstract][Full Text] [Related]
9. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.
Mushtaq S; Warner M; Johnson AP; Livermore DM
J Antimicrob Chemother; 2004 Sep; 54(3):617-20. PubMed ID: 15321983
[TBL] [Abstract][Full Text] [Related]
10. Origin, structure, and activity in vitro and in vivo of dalbavancin.
Malabarba A; Goldstein BP
J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii15-20. PubMed ID: 15750032
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
[TBL] [Abstract][Full Text] [Related]
12. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
Biedenbach DJ; Ross JE; Fritsche TR; Sader HS; Jones RN
J Clin Microbiol; 2007 Mar; 45(3):998-1004. PubMed ID: 17215346
[TBL] [Abstract][Full Text] [Related]
13. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
[TBL] [Abstract][Full Text] [Related]
14. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
Jones RN; Stilwell MG; Sader HS; Fritsche TR; Goldstein BP
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):149-53. PubMed ID: 16426793
[TBL] [Abstract][Full Text] [Related]
15. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
[TBL] [Abstract][Full Text] [Related]
17. Vancomycin versus teicoplanin in the therapy of experimental methicillin-resistant Staphylococcus aureus (MRSA) meningitis.
Sipahi OR; Arda B; Yurtseven T; Sipahi H; Ozgiray E; Suntur BM; Ulusoy S
Int J Antimicrob Agents; 2005 Nov; 26(5):412-5. PubMed ID: 16221540
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of vancomycin, teicoplanin and fusidic acid as prophylactic agents in prevention of vascular graft infection: an experimental study in rat.
Yasim A; Gul M; Atahan E; Ciragil P; Aral M; Ergun Y
Eur J Vasc Endovasc Surg; 2006 Mar; 31(3):274-9. PubMed ID: 16360328
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal activity and resistance development profiling of dalbavancin.
Goldstein BP; Draghi DC; Sheehan DJ; Hogan P; Sahm DF
Antimicrob Agents Chemother; 2007 Apr; 51(4):1150-4. PubMed ID: 17220411
[TBL] [Abstract][Full Text] [Related]
20. A vancomycin-heparin lock solution for prevention of nosocomial bloodstream infection in critically ill neonates with peripherally inserted central venous catheters: a prospective, randomized trial.
Garland JS; Alex CP; Henrickson KJ; McAuliffe TL; Maki DG
Pediatrics; 2005 Aug; 116(2):e198-205. PubMed ID: 15995005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
